

HIGH PERFORMANCE ANTIBODIES ... AND MORE

ProSci Incorporated Toll Free: +1 (888) 5139525
12170 Flint Place Local: +1 (858) 5132638
Poway, CA 92064 Fax: +1 (858) 5132692

## PLAU Antibody

CATALOG NUMBER: 45-114
250 kDa
150 kDa
100 kDa
75 kDa
50 kDa
37 kDa

25 kDa
20 kDa

15 kDa
10 kDa

Western Blot ( $0.3 \mathrm{ug} / \mathrm{ml}$ ) staining of 293 lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Specifications SPECIES REACTIVITY: Human TESTED APPLICATIONS: ELISA, WB
APPLICATIONS:
ELISA: antibody detection limit dilution 1:8000. Western Blot: Approx 48kDa band observed in lysates of human kidney fibroblast cell line HEK293 (calculated MW of 48.5kDa according to NP_002649.1). Recommended concentration: $0.3-1.0 \mathrm{ug} / \mathrm{ml}$. A minor band was also consistently observed at appox 35 kDa .
POSITIVE CONTROL: 1) Cat. No. 1210-293 Cell Lysate

SPECIFICITY:
IMMUNOGEN:
HOST SPECIES:

This antibody is expected to recognise both reported isoforms.
PLAU antibody was raised against a 14 amino acid synthetic peptide near the C-Terminus of PLAU.
Goat

## Properties

PURIFICATION:
PLAU antibody was purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
PHYSICAL STATE:
BUFFER:
CONCENTRATION:
STORAGE CONDITIONS:
CLONALITY:
Liquid
PLAU antibody is supplied in Tris saline, $0.02 \%$ sodium azide, pH 7.3 with $0.5 \%$ bovine serum albumin. $500 \mathrm{ug} / \mathrm{mL}$

Aliquot and store at $-20^{\circ} \mathrm{C}$. Minimize freezing and thawing.

CONJUATE:

Additional Info
ALTERNATE NAMES:
PLAU, plasminogen activator, urokinase, HGNC:9052, ATF, UPA, URK, u-PA, U-plasminogen activator, antagonist of uPA, urinary, urokinase plasminogen activator, urokinase-type plasminogen activator aminoterminal fragment, urokinase-t, QPD, BDPLT5
ACCESSION NO.:
NP_002649.1
PROTEIN GI NO.:

| OFFICIAL SYMBOL: | PLAU |
| :--- | :---: |
| GENE ID: | 5328 |

## Background

REFERENCES:

1) Morgan H, Hill PA. Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int. 2005 Feb 08;5(1):1.

## FOR RESEARCH USE ONLY

